Con­cert’s ini­tial alope­cia da­ta fall short against Pfiz­er, prompt­ing in­vestor blow back

An in­ter­im analy­sis of mid-stage da­ta on Con­cert Phar­ma­ceu­ti­cals’ $CNCE JAK in­hibitor for alope­cia may have thinned its po­ten­tial against Pfiz­er’s $PFE ri­val drugs in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER